- Email:
Glial Progenitor Differentiation Services
Introduction
Glial progenitor cells are critical for myelin regeneration and neuronal metabolic support. In vitro generation of these cells has long been limited by low efficiency. Creative Biolabs provides professional Glial Progenitor Differentiation services using transcription-factor-driven induction and the STEMOD™ platform. The service yields highly purified, functional glial cells, shortens differentiation time, and supports efficient disease modeling, drug screening, and CNS therapeutic research.
Discover How We Can Help - Request a Consultation
Glial Progenitor Differentiation Services
Glial progenitor differentiation converts human pluripotent stem cells into expandable glial progenitor cells (GPCs) that further mature into astrocytes, oligodendrocytes, and microglia---the major glial subtypes of the central nervous system. These cells regulate neuronal support, myelination, synaptic function, inflammation, and brain homeostasis, making them essential for reliable neurodevelopmental and neurodegenerative modeling.
Astrocyte Differentiation
Generates mature, functional, and regionally patterned astrocytes expressing GFAP, S100β, and ALDH1L1. These astrocytes support synaptic activity, modulate neuroinflammation, and enable modeling of reactive gliosis, autism, Alzheimer's disease, and Parkinson's disease.
Microglia Differentiation
Produces functional myeloid-lineage microglia expressing IBA1, CD11b, and TMEM119. They recapitulate phagocytosis, inflammatory responses, and immune surveillance, ideal for studying neuroinflammation, neurodegeneration, and brain aging.
Oligodendrocyte Differentiation
Differentiates into oligodendrocyte progenitor cells (OPCs, PDGFRα+/O4+) and mature myelinating oligodendrocytes (MBP+/PLP+). Supports myelination research, drug screening, and modeling of multiple sclerosis, spinal cord injury, and leukodystrophies.
Applications
- Neuroinflammation, reactive gliosis, and myelination repair
- Neurodegenerative and neurodevelopmental disorders
- High-throughput drug screening and safety assessment
- Neuron-glia co-culture and 3D assembloid models
Workflow
The differentiation process at Creative Biolabs is a high-precision journey from pluripotency to functional maturity. Our workflow is designed for transparency and reproducibility:
What We Can Offer
At Creative Biolabs, we provide a versatile and scalable suite of solutions for Glial Progenitor Differentiation, meticulously designed to meet the rigorous demands of industrial R&D and academic excellence. Our offerings include:
All-side Customization
We provide fully bespoke differentiation protocols tailored to your specific research needs, including patient-specific iPSC reprogramming and targeted gene editing.
Scalable Production Architecture
One-stop differentiation services ranging from pilot-scale laboratory batches to large-scale industrial quantities suitable for high-throughput screening (HTS).
High-Fidelity Disease Modeling
Access to pre-engineered glial models for Alzheimer's, Parkinson's, ALS, and MS, ensuring pathological relevance from day one.
Optimized Expression & Yield
Advanced codon optimization and media formulation techniques to maximize the expression of therapeutic proteins or specific glial markers in human cell systems.
Rigorous Quality Framework
Application of Quality-by-Design (QbD) principles and process analytical techniques (PAT) to guarantee the consistency and stability of every cell bank and differentiated lot.
GMP-Ready Documentation
Full traceability and assessment of strain/cell origin, ensuring that all procedures align with the highest quality assurance standards and basic principles of Good Manufacturing Practice (GMP).
Advanced Analytic Toolset
Utilization of high-standard QC tools, including single-cell RNA sequencing and multi-electrode array (MEA) functional validation, to quantify and evaluate product quality.
Experience the Creative Biolabs Advantage - Get a Quote Today
Case Study
To investigate the influence of the humanized HD glial microenvironment on normal glial progenitor cells, researchers transplanted mCherry-labeled wild-type human GPCs into the striatum of 36-week-old HD chimeric mice, and monitored cell proliferation, migration, and replacement via histological assays, while comparing expansion efficiency under different transplantation conditions.
The results showed that wild-type GPCs gradually and persistently replaced host HD glial cells, forming mutually exclusive spatial domains. Astrocyte turnover was slower, and competition occurred mainly at the GPC stage. Allogeneic GPC replacement proceeded more slowly than xenogeneic transplantation, indicating stronger but surmountable competitive resistance.
Control experiments excluded reporter gene toxicity, validating that GPC transplantation enables functional glial reconstruction, providing key evidence for glial replacement therapy in HD.
Fig.1 Using the mHTT model and hGCP cells, the competition among adult brain cells was studied.1
Customer Reviews
FAQs
Q: Can these cells be used for 3D organoid cultures?
A: Yes, our differentiated GPCs are highly compatible with 3D brain spheroids and organoids, providing the necessary glial component for complex CNS modeling.
Q: What markers are used to verify oligodendrocyte maturity?
A: We typically use O4 and PDGFRα for progenitors, and MBP (Myelin Basic Protein) and PLP for mature, myelinating oligodendrocytes.
Q: Are your protocols serum-free?
A: Yes, we utilize chemically defined, serum-free media to ensure maximum reproducibility and to avoid the variability associated with animal-derived components.
Q: Can you differentiate cells from patient-specific iPSC lines?
A: Yes. We offer custom differentiation services where you can send us your patient-derived lines, and we will apply our optimized protocols to generate the target glial population.
Q: How do your iPSC-derived glia compare to primary human cells?
A: Our iPSC-derived glia shows high transcriptomic correlation with primary tissue and offer the added advantage of scalability and the ability to engineer specific genetic backgrounds.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Vieira, Ricardo, et al. "Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain." Nature biotechnology 42.5 (2024): 719-730. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41587-023-01798-5.
For Research Use Only. Not For Clinical Use.